



*Meeting organised in collaboration with
Working Group 27 on Acute Cardiac Care
of the European Society of Cardiology*

5th International Meeting Intensive Cardiac Care

Tel Aviv, Israel
October 14-16, 2007

Program

<http://www.isas.co.il/cardiac-care2007>

ORGANIZING COMMITTEE

Co-Chairmen

Joseph S. Alpert, USA
Alexander Battler, Israel
Yonathan Hasin, Israel

Secretary

Doron Zahger, Israel

Nursing Coordinator

Nurit Baruch, Israel

Invited Faculty

Ezra Amsterdam, USA
Jean Pierre Bassand, France
Peter B. Berger, USA
Steven Borzak, USA
Bojan Cercek, USA
Peter Clemmensen, Denmark
Nicolas Danchin, France
Raffaele De Caterina, Italy
Roberto Ferrari, Italy
Dan Fintel, USA
Claudio Fresco, Italy
Jeffrey Goldberger, USA
Magda Heras, Spain
John Horowitz, Australia
Allan Jaffe, USA
Edo Kaluski, USA
Sanjay Kaul, USA
Ruud W. Koster, Netherlands
Alan Maisel, USA
Gianfranco Mazzotta, Italy
J.T. Parisis, Greece
Andrew Rhodes, UK
Gabriel Steg, France
Steven R. Steinhubl, USA
Marco Tubaro, Italy
Alec Vahanian, France
Frans Van de Werf, Belgium
Elena Vasilieva, Russia
Zaheer Yousef, UK

AUSPICES



Israel Heart Society



Israel Heart Society
Working Group on Intensive
Cardiac Care

Organized in Collaboration with:



European Society of Cardiology
Working Group on Acute Cardiac
Care



European Resuscitation Council



Society for the Advancement of
Cardiac Nursing in Israel



International Society for Heart
Research

Local Faculty and Organizing Committee

Yoram Agmon	Amos Katz
Yaniv Almog	Andre Keren
Doron Aronson	Gad Keren
Abid Assali	Eli Konen
Shaul Atar	Ran Kornowski
Oded Ayzenberg	Jacob Lavee
Jonathan Balkin	Jonathan Leor
Shmuel Banai	Eli Lev
Israel Barbash	Basil S. Lewis
Tuvia Ben Gal	Chaim Lotan
Jesaia Benhorin	Walter Markiewicz
Benjamin Brenner	Shlomo Matetzky
Carlos Cafri	Simcha Meisel
Avraham Caspi	Morris Mosseri
Haim D. Danenberg	Menachem Nahir
Micha Eldar	Arthur Pollack
Moshe Flugelman	Avi Porath
Dov Freimark	Avital Porter
Shmuel Fuchs	Uri Rosenshein
Dan Gilon	Arie Roth
Harel Gilutz	Yoseph Rozenman
Michael Glikson	Alex Sagie
Victor Guetta	Gideon Sahar
Haim Hammerman	Boris Strasberg
David Hasdai	Dan Tzivoni
Yaakov Henkin	David Varon
Hanoch Hod	Zvi Vered
Zaza Iakobishvili	A. Teddy Weiss
Reuben Iliia	

Scientific Advisory Committee

Ottavio Alfieri, Italy	Bulent Gorenek, Turkey	Markku Nieminen, Finland
Giuseppe Ambrosio, Italy	Judith S. Hochman, USA	Roberto Perriri, Italy
Hector Bueno, Spain	Sabino Iliceto, Italy	Massimo Santini, Italy
Michele Cortellaro, Italy	Petr Jansky, Czech Republic	Jacob Shani, USA
Filippo Crea, Italy	Amir Kol, Italy	Maarten Simoons, The Netherlands
Antonio Di Chiara, Italy	Michael S. Lauer, USA	Fritz Sterz, Austria
Giuseppe Di Pasquale, Italy	John Lekakis, Greece	Michal Tendera, Poland
Uri Elkayam, USA	Amir Lerman, USA	Ilja Zakke, Latvia
Rafael Ferreira, Portugal	José López-Sendón, Spain	
Marcello Galvani, Italy	Gilles Montalescot, France	
Anselm K. Gitt, Germany	Francesco Musumeci, Italy	

Dear Colleague,

Welcome to the 5th International Meeting on Intensive Cardiac Care. The Meeting features three parallel sessions, with over 100 presentations, including: satellite symposia, plenary lectures, debates, clinical interactive case presentations, round-table discussions, poster presentations and a parallel nursing stream. The program is diverse and includes content that will satisfy all participants interested in acute cardiac care.

The Meeting is held under the auspices of the Israel Heart Society, and in collaboration with the ESC Working Group on Acute Cardiac Care, the Israel Working Group on Intensive Cardiac Care of the IHS, the International Society for Heart Research and the Society for the Advancement of Cardiac Nursing in Israel.

We hope you will take part in both the state-of-the-art scientific program and the entertaining social and cultural events. We especially invite you to our October 15 guided evening tour to the ancient Roman port of Caesaria followed by a festive meal. Our unique atmosphere of a modern vibrant society living alongside the architecture, museums and sites of 3000 years of history, since the time of King David, guarantees to provide you with an unforgettable experience.

Sincerely,

Joseph S. Alpert

Alexander Battler

Yonathan Hasin

08:30-10:00 **HALL A** *simultaneous translation*

Cardiogenic shock

Chairs: *E. Kaluski, USA, R. Ilia, Israel*

08:30-08:52

Trends in cardiogenic shock in the era of primary PCI: incidence, predictors, outcomes

D. Hasdai, Israel

08:52-09:15

NOS inhibitors

E. Kaluski, USA

09:15-09:37

The intra-aortic balloon pump: current status and new technologies

O. Ayzenberg, Israel

09:37-10:00

New horizons of cardiogenic shock: pump enhancement or replacement

J. Lavee, Israel

08:30-10:00 **HALL B**

Valvular emergencies in the ICCU

Chairs: *A. Sagie, D. Gilon, Israel*

08:30-08:52

Emergency situations in valvular heart disease

A. Vahanian, France

08:52-09:15

Echocardiography for the diagnosis of acute emergencies in the CCU

A. Sagie, Israel

09:15-09:37

Acute valvular emergencies – the surgeon's perspective

G. Sahar, Israel

09:37-10:00

The use of new percutaneous valve interventions

A. Vahanian, France

08:30-10:00 **HALL C**

PCI and beyond for acute MI

Chairs: *M. Mosseri, Israel, G. Steg, France*

08:30-08:48

Optimal pathways to achieve reperfusion in STEMI

J.P. Bassand, France

08:48-09:06

PCI for STEMI: the role of new devices

V. Guetta, Israel

09:06-09:24

Adjunctive pharmacotherapy

R. De Caterina, Italy

09:24-09:42

Drug eluting stents in acute MI

S. Banai, Israel

09:42-10:00

Interaction of lysis and PCI in STEMI

G. Steg, France

10:00-10:30 Coffee Break & Posters

10:30-11:30 **HALL A** *simultaneous translation*

Opening ceremony/keynote lectures

Greetings:

Y. Hasin, A. Battler, J.S. Alpert

Conference co-chairs

R. Ferrari, President Elect, ESC

M. Tubaro, Chairman, ESC Working Group Acute Cardiac Care

B. S. Lewis, President, Israel Heart Society

Program Overview:

D. Zahger, Conference secretary

Keynote lectures:

10:50-11:10

Mechanisms of ventricular remodeling

R. Ferrari, Italy

11:10-11:30

Current role of revascularization in acute coronary syndromes

F. Van de Werf, Belgium

11:30-13:00 **HALL A** *simultaneous translation*

Nursing session I

Chair: *N. Baruch, Israel*

11:30-11:40

Medical art therapy: influence on quality of life and compliance of patients with advanced heart failure
N. Sela, Israel

11:40-11:50

Case presentation: Pulmonary emboli with cardiogenic shock
D. Bendelac, Israel

11:50-12:00

Phlebitis as a result of I.V. amiodarone treatment
B. Zamir, Israel

12:00-12:10

Factors that influence late arrival to hospital in acute myocardial infarction
M. Abedelmoati, Israel

12:10-12:20

The prognostic implication of anemia in patients after myocardial infarction referred for CABG
M. Bartal, Israel

12:20-12:30

Preparing patients and their family members before transfer from ICCU to the department
S. Dayan, Israel

12:30-12:40

Vital exhaustion syndrome following acute myocardial infarction – clinical and nursing aspects
O. Kolpak, Israel

12:40-12:50

Improvement in the nutritional state of patients in the intensive care unit
R. Area Yaish, Israel

12:50-13:00

Trans fatty acids and coronary heart disease
Z. Dadashev, Israel

11:30-13:00 **HALL B**

Statis post acute coronary syndromes (Pfizer satellite)

Chairs: *A. Shotan, D. Tzivoni, Israel*

11:30-12:06

Debate: The lower (LDL)-the better
Protagonist: *Y. Rozenman, Israel*
Antagonist: *J. Leor, Israel*

12:06-12:24

High dose statins – are they safe?
Y. Henkin, Israel

12:24-12:42

Non-lipid effects of statins
S. Banai, Israel

12:42-13:00

How soon should aggressive lipid lowering be started?
D. Fintel, USA

11:30-13:00 **HALL C**

Pharmacological management of acute heart failure (Abbott satellite)

Chairs: *D. Freimark, A. Keren, Israel*

11:30-11:55

Positive inotropic agents
D. Freimark, Israel

11:55-12:20

Levosimendan – Rationale and clinical experience
J. T. Parissis, Greece

12:20-12:45

Case presentations
T. Ben Gal, M. Nahir, Israel

12:45-13:00 Panel Discussion

13:00-15:00 Lunch

Conference Level (GSK satellite)

**Update in thrombosis:
The role of new molecules for ACS**

Chairs: *Y. Hasin, Israel,
J.P. Bassand, France*

Fondaparinux – the hematological perspective

B. Brenner, Israel

Oasis-5: Impact of bleeding on outcome, analysis of subgroups

G. Steg, France

Oasis-6: Impact on outcome of adjunctive therapy with fondaparinux: Fondaparinux in PCI

J.P. Bassand, France

15:00-16:30 HALL A simultaneous translation

The complicated patient in the ICCU

Chairs: *J. Balkin, A. Pollack, Israel*

15:00-15:18

Swan Ganz catheterization: always, often, or never?

J.T. Parisis, Greece

15:18-15:36

Management of sub-massive pulmonary embolism

H. Hod, Israel

15:36-15:54

The role of ventilatory support in the management of heart failure – a practical approach

Y. Almog, Israel

15:54 -16:12

New less invasive tools to monitor the circulation

A. Rhodes, UK

16:12-16:30

CPR in 2007 – what is new?

R.W. Koster, Netherlands

15:00-16:30 HALL B

No reflow – the Achilles heel of reperfusion therapy

Chairs: *D. Zahger, U. Rosenshein, Israel*

15:00-15:18

Pathophysiology of no reflow

M. Flugelman, Israel

15:18-15:36

Recognition of no reflow

B. Cercek, USA

15:36-15:54

Can no reflow be predicted on admission?

D. Zahger, Israel

15:54-16:12

Pharmacological management of no reflow

R. Ilija, Israel

16:12-16:30

Mechanical management of no reflow

V. Guetta, Israel

15:00-16:30 HALL C

Case discussions in ACS in view of the guidelines

Chairs: *A. Battler, A. Assali, Israel*

Participants: *J.P. Bassand,*

N. Danchin, J. Alpert, M. Tubaro, Y. Hasin

16:30-17:00 Coffee Break & Posters**17:00-18:30 HALL A simultaneous translation**

ACS in high risk patients: diabetes and renal failure

Chairs: *H. Gilutz, J. Benhorin, Israel*

17:00-17:18

Glycaemic control in the ICCU

A. Rhodes, UK

17:18-17:36

The impact of chronic renal failure on prognosis and management

H. Hammerman, Israel

17:36-17:54

The impact of anemia

D. Aronson, Israel

17:54-18:12

Antecedent heart failure or valve disease

Z. Iakobishvili, Israel

18:12-18:30

Long term prognosis after AMI – insights from GISSI

C. Fresco, Italy

17:00-18:30 **HALL B**

The role of inflammation in ACS

Chairs: *S. Meisel, A. Caspi, Israel*

17:00-17:18

Metabolic syndrome, inflammation and coronary disease

J. Horowitz, Australia

17:18-17:36

The role of CRP as a marker and as a pathogen in ACS

H. Danenberg, Israel

17:36-17:54

Polyvascular disease and ACS

G. Steg, France

17:54-18:12

The anti-inflammatory and anti-atherogenic effects of omega-3 fatty acids - from bedside to bench

R. De Caterina, Italy

18:12-18:30

Anti diabetic medications and outcomes of ACS

N. Danchin, France

18:45

Optional: Guided tour to the ancient Roman port city of Caesaria, followed by a festive meal and return to Tel Aviv 60 Euro

08:30-10:00 **HALL A** *simultaneous translation*
Controversies in ACS

Chairs: *Y. Rozenman, G. Keren, Israel*

08:30-09:15

Every patient with non-ST elevation ACS should have coronary angiography and intervention

Protagonist: *C. Lotan, Israel*

Antagonist: *S. Kaul, USA*

09:15-10:00

Drug eluting stents are safe and should be used for most patients

Protagonist: *R. Kornowski, Israel*

Antagonist: *S. Kaul, USA*

08:30-10:00 **HALL B**

Non-ST elevation ACS

Chairs: *D. Hasdai, Israel, P.B. Berger, USA*

08:30-08:48

Who is the low risk patient?

M. Tubaro, Italy

08:48-09:06

Clopidogrel: For whom?

For how long?

P.B. Berger, USA

09:06-09:24

Optimizing anti-thrombotic therapy

M. Heras, Spain

09:24-09:42

Role of the invasive approach - insights from CRUSADE

E. Amsterdam, USA

09:42-10:00

The new NSTEMI ACS guidelines

J.P. Bassand, France

08:30-10:00 **HALL C**

Electrophysiology in the CCU

Chairs: *M. Glikson, B. Strasberg, Israel*

08:30-08:48

Pacemaker and ICD emergencies for the CCU physician

M. Glikson, Israel

08:48-09:06

Should all patients with a low EF receive ICD's? Risk stratification beyond EF

J. Goldberger, USA

09:06-09:24

The new AF guidelines

A. Katz, Israel

09:24-09:42

Update on CRT

Z. Yousef, UK

09:42-10:00

VT storm and the role of ablation

M. Eldar, Israel

08:30-10:00 **HALL D**

The new AMI definition

Chairs: *H. Hod, Israel, J. Alpert, USA*

08:30-08:48

The universal definition of AMI - what has changed in 2007?

J. Alpert, USA

08:48-09:06

New biomarkers in acute coronary syndromes

A. Jaffe, USA

09:06-09:24

What was the impact of the new AMI definition?

A. Porath, Israel

09:24- 09:42
 Implication of the new definition for
 PCI and CABG patients
G. Steg, France

09:42-10:00
 "Transient ST elevation MI" -
 a new entity?
S. Matetzky, Israel

10:00-10:30 Coffee Break & Posters

10:30-12:00 **HALL A** *simultaneous translation*
Nursing session II
 Chairs: *M. Bartal, F. Heberfeld, Israel*

10:30-10:42
 Where is the point of no return in
 the use of vasopressors? Defining
 maximal therapeutic dosage of
 vasopressors in intensive care
J. Benbenishty, Israel

10:42-10:55
 Combined intensive lifestyle
 counseling and pharmacologic lipid
 treatment further improves lipid
 profile compared with usual care
 cholesterol-lowering drugs in
 patients with coronary artery disease
D. Barkai, Israel

10:55-11:07
 Uncertainty among immediate
 family members hospitalized in
 the coronary care unit
G. Kogen, Israel

11:07-11:20
 The nurse as a coordinator of a multi-
 disciplinary team for the treatment
 of patients with CHF in the
 community
H. Paz, Israel

11:20-11:34
 Research questions evaluated in
 ergometry stress test
M. Azencot, Israel

11:34-11:47
 Case presentation: Coronary artery
 disease in women
M. Rassin, Israel

11:47-12:00
 Delirium uncovers the myths
M. Zoref, Israel

10:30-12:00 **HALL B**
Biomarkers – all for one?
One for all? (Biosite satellite)
 Chairs: *A. Maisel, USA, M. Tubaro, Italy*

10:30-11:10
 The emerging role of BNP in the
 diagnosis and management of heart
 failure
A. Maisel, USA

11:10-11:50
 Multi-biomarker approach in risk
 stratification of ACS
S. Meisel, Israel

11:50-12:00 Panel Discussion

10:30-12:00 **HALL C**
Pre-hospital reperfusion
 Chairs: *A.T. Weiss, A. Roth, Israel*

10:30-10:48
 Historic overview
A.T. Weiss, Israel

10:48-11:06
 Teletransmission of the EKG in ACS
P. Clemmensen, Denmark

11:06-11:24
 Pre-hospital administration of anti-
 thrombotic medications in STEMI
N. Danchin, France

11:24-11:42
 When is pre-hospital thrombolysis
 preferable to primary PCI?
G. Steg, France

11:42-12:00

Is there a role for IIb/IIIa receptor antagonists in the pre-hospital setting?

E. Vasilieva, Russia

10:30-12:00 **HALL D**

**Acute decompensated heart failure:
New agents and challenging cases**

Chairs: *Y. Hasin, Israel, J.T. Parissis, Greece*

10:30-10:50

Nesiritide

S. Borzak, USA

10:50-11:10

Endothelin antagonists

Z. Vered, Israel

11:10-11:30

Vasopressin antagonists

T. Ben Gal, Israel

11:30-11:50

Case presentation

A. Porter, Israel

11:50-12:00 Panel Discussion

12:00-14:00 Lunch

Conference Level

(Sanofi Aventis satellite)

**Weighing the evidence -
antithrombotic therapy in
acute MI and PCI**

Chairs: *Y. Rozenman, S. Banai, Israel*

Optimizing anticoagulation in STEMI

P. B. Berger, USA

Anticoagulation in NSTEMI:

the role of dose adjustment

Y. Rozenman, Israel

Optimal management in the
catheterization laboratory

V. Guetta, Israel

14:00-15:30 **HALL A** *simultaneous translation*

**Risk stratification of chest pain in
the ER**

Chairs: *S. Atar, H. Hod, Israel*

14:00-14:18

Current status of the chest pain unit

E. Amsterdam, USA

14:18-14:36

Hand-carried ultrasound for
evaluation of chest pain in the ER

S. Atar, Israel

14:36-14:54

Troponin elevation – is it always ACS?

A. Jaffe, USA

14:54-15:12

The role of stress imaging in the ER

Y. Agmon, Israel

15:12-15:30

The role of CT in chest pain triage

E. Konen, Israel

14:00-15:30 **HALL B**

**Pharmacological management of
STEMI**

Chairs: *H. Hammerman,*

W. Markiewicz, Israel

14:00-14:18

Pre-hospital thrombolysis:
a challenge to primary PCI?

N. Danchin, France

14:18-14:36

Optimal adjunctive therapy after
thrombolysis for STEMI

J.P. Bassand, France

14:36-14:54

The role of clopidogrel

P.B. Berger, USA

- 14:54-15:12
 What is the role of thrombolytic therapy in 2007?
G. Mazzotta, Italy
- 15:12-15:30
 Warfarin, aspirin and clopidogrel?
M. Heras, Spain

- 16:45-17:07
 Summary of clinical trials
S. Fuchs, Israel
- 17:07-17:30
 Alternatives for myocardial regeneration and repair
J. Leor, Israel

14:00-15:30 **HALL C**
Resistance to anti-platelet therapy
 Chairs: *S. Matetzky, M. Eldar, Israel*

- 14:00-14:30
 Platelet aggregation: physiology and clinical assessment
S.R. Steinhubl, USA

- 14:30-14:45
 Aspirin resistance
D. Varon, Israel

- 14:45-15:00
 Clopidogrel resistance
S. Matetzky, Israel

- 15:00-15:15
 The future of anti-platelet therapy
E. Lev, Israel

- 15:15-15:30 Discussion

15:30-16:00 Coffee Break & Posters

16:00-17:30 **HALL A** *simultaneous translation*
Cardiac stem cell therapy revisited
 Chairs: *J. Leor, A. Battler, Israel*

- 16:00-16:22
 Cardiac stem cells
I. Barbash, Israel

- 16:22-16:45
 Safety and dosage of cell therapy in collateral dependent circulation
M. Flugelman, Israel

16:00-17:30 **HALL B**
PCI for AMI
 Chairs: *C. Cafri, C. Lotan, Israel*

- 16:00-16:18
 Primary PCI – lessons from recent trials
J. Horowitz, Australia

- 16:18-16:36
 Validity of rescue and facilitated angioplasty for ST elevation MI
P.B. Berger, USA

- 16:36-16:54
 Is late reperfusion beneficial?
Z. Yousef, UK

- 16:54-17:12
 PCI related delay in STEMI - fact or fiction?
P. Clemmensen, Denmark

- 17:12-17:30
 How to shorten door to balloon time in the real world?
M. Nahir, Israel

Venue:

David Intercontinental Hotel
12 Kaufman St., Tel Aviv
Tel: +972-3-7951111

Conference Telephone:

+972(0)506-758792

Secretariat:

5th International Meeting - ICCU2007
POB 574, Jerusalem, 91004, Israel

Email: seminars@isas.co.il

Tel: +972-2-6520574

Fax: +972-2-6520558

Transportation to the Airport:

Ben-Gurion International Airport is located 20 minutes from Tel Aviv. Taxi service and a modern airport train provide fast and economic transportation.

Tour and Festive meal

Monday, October 15, 18:45-24:00

Optional: Guided tour to the ancient Roman port city of Caesaria, followed by a festive meal and return to Tel Aviv

Price: **60 Euro**

Tickets available at hospitality desk.

Banking

Banks are open from 08:30 until 13:30 and from 16:00-17:00 on certain afternoons. The present rate of exchange is about 4 NIS (Israeli shekels) to 1 US dollar, 5.60 NIS to 1 Euro.

Taxi Cabs

Use meter for all trips. 15 minute drives inside Tel Aviv should cost about 30 NIS. The trip to the airport costs about 100 NIS.

Maps of Israel and general tourist information are available at the Hotel concierge.

Tours:

Conference tours available at hospitality desk. For further information contact tour guide Mr. Eli Gertler **+972-52-2639516**

**CME:**

This program is accredited by the European Board for Accreditation in Cardiology (EBAC) for 12 hours of external CME credits.

Each participant should claim only those hours of credit that have actually been spent in the educational activity. EBAC works according to the quality standards of the European Accreditation Council for Continuing Medical Education (EACCME), which is an institution of the European Union of Medical Specialists (UEMS). EACCME credits are recognized by the American Medical Association towards the Physician's Recognition Award (PRA). To convert EACCME credit to AMA PRA category 1 credit, contact the AMA.

Full Day Tours

Tour 2: The North

Tuesday, October 16 (depart 8 AM)

Depart Tel Aviv and continue north through the orange groves of Sharon to Netanya. Follow the coastal road through the greenery of Hadera. Pass King Herod's ancient Roman port city of Caesaria, Hippodrome and Crusader buildings. Pass Zichron Yaakov and hear about the vineyards and city Baron Rothschild built nearly 100 years ago. Pass the Carmel Mountains, Stella Maris, Bahai Gardens and exit Haifa north towards Acco. Break for lunch (not included).

Visit Crusader sites and UNESCO Heritage site of the underground city. Tour ancient port city, the marketplace and time permitting, the citadel prison where the British jailed Israel's Lehi and pre-state fighters. Return to Tel Aviv about 6 PM. (price €77)

Tour 3: Masada & Dead Sea

Wednesday, October 17 (depart 8 AM)

Drive to Jerusalem and descend through the beautiful scenery of the Judean Desert to the lowest point on Earth - the Dead Sea. Drive along the sea, pass by Qumran where the Dead Sea Scrolls were found and continue to Masada - the ancient fortress built by Herod the Great in the 1st Century B.C.E. which was the last Jewish stronghold during the revolt against the Romans. Bring water, hat, walking shoes, bathing suit & towel (there will be time for a dip in the Dead Sea). Lunch not included.

(price €97)

New Tour: Jerusalem

Thursday, October 18 (depart 8:15 AM)

Depart Tel Aviv via Jaffa which served as port for Jerusalem 3000 years ago. Pass through biblical Emek Ayalon, the monastery of Latrun and hear the story of "Jesus and the good thief". Continue up through Shaar Ha-Gai, the only approach to Jerusalem during the 1948 War of Independence. After lunch (not included) visit the Old-City of Jerusalem

and tour on foot, Mt. Zion, King David's Tomb, the Room of the Last-Supper, Dormition Church, Zion Gate, and three Old City Quarters: Armenian, Jewish and Christian. Visit the Cardo, the Western Wall, Via Dolorosa, Church of the Tomb, and exit the Old City via the Jaffa Gate. We will return to Tel Aviv via Jerusalem's northern highway passing the Prophet Samuel's Tomb and other sites. Return to Tel Aviv about 6 PM. (price €79)

Half Day Tour

New Tour: Tel Aviv - Jaffa

Monday, October 15 (13:00-17:30)

Tour Jaffa, the ancient port city and the shuk (marketplace), Mosque Hasan Bek, and experience ancient history from biblical Joshua, Romans, Greek, Macabbeans & Napoleon. Visit the Etzel Museum describing Israel's modern history until the 1948 War of Independence. Afterwards tour the first homes of Tel Aviv in the Suzanne Dalal Center. Witness the rejuvenation project of this almost 100 year old section of Tel Aviv. (price €35)

Tours exclusively for conference participants and accompanying persons.

- All itineraries are subject to change and require a minimum of 15 participants per tour.
- For additional tours and extensions, please contact the Secretariat.
- Pickup from lobby of all conference hotels.

Guide: Mr. Eli Gertler
+972-52-2639516

ABBOTT INTERNATIONAL

Atidim Science Park, Bldg 4
Tel Aviv 61580, Israel
Tel: 03-7691000
Fax: 03-6494973
doran.hai@abbott.com

For over 100 years, Abbott as a global, broad-based health care company is devoted to discovering new medicines, new technologies and new ways to manage health.

Our products span the continuum of care, from nutritional products and laboratory diagnostics through medical devices and pharmaceutical therapies. Our comprehensive line of products encircles life itself - addressing important health needs from infancy to the golden years.

Today, 65,000 Abbott employees around the world share the passion for "Turning Science Into Caring". It's a commitment to focusing on what matters most: life and the potential it holds when we are feeling our best.

Abbott's promise as a company is in the promise that our work holds for the people we serve.

Simdax (levosimendan) is a new calcium sensitizer and K-ATP channel opener. Compared with other inodilators, it improves myocardial contractility without increasing oxygen requirements and induces peripheral and coronary vasodilation with a potential anti-stunning, anti-ischæmic effect. (Evidence-based use of levosimendan in different clinical settings. Eur Heart J. 2006 Aug;27(16):1908-20).

Simdax is indicated for the short-term treatment of acutely decompensated severe chronic heart failure. Simdax should only be used as add-on therapy in situations where conventional therapy with e.g. diuretics, ACE-inhibitors and digitalis is not sufficient and where there is a need for inotropic support.

A.M.I. TECHNOLOGIES LTD.

22 Hanagar St.
Neve Ne'eman Industrial Zone
P.O.Box 596, Hod Hasharon, Israel
Tel: 09-7760300
Fax: 09-7760303
amitech@ami.co.il

A.M.I Technologies Ltd. is the sole Israeli representative and distributor for leading international medical equipment manufacturers.

The company specializes in importing and marketing unique disposable products, implants and capital equipment for Israeli hospitals, clinics and doctors.

A.M.I Technologies was established in 1986 and is considered a leader in the field of medical equipment and supplies. The company's outstanding reputation can be credited to the variety of solutions provided by its products and technologies, the excellent quality of its product lines, the dedicated customer service and the high degree of satisfaction expressed by customers.

A.M.I's fields of activity can be divided into 5 main divisions:

- Cardiology
- Esthetic & Plastic Surgery, Rehabilitation
- Interventional: Radiology, Critical Care, Anesthesia and Vascular Surgery
- Orthopedics
- Urology & Gastroenterology

In cardiology A.M.I is a market leader in the following areas:

- Cardiac Assist-AutoCat 2 Wave relies on a unique combination of FiberOptix sensor technology, aortic flow timing, proprietary Wave software and AutoPilot mode of operation to achieve its high level of performance - even in patients with severe arrhythmias.
- Acist Contract Delivery System & Diaposble.

- Pediatric Intervention - Angioplasty and Valvuloplasty catheters, Bare and Covered Stent.
- Septal Occluder - Ingenious ASD and PFO closure.
- Mitral stenosis - The Inoue - Balloon Catheter was developed for treating Mitral stenosis.

BOSTON SCIENTIFIC

Kibbutz Gilil Yam, Herzliya
Tel: 09-9617505
Fax: 09-9617576

Boston Scientific (NYSE: BSX) is a worldwide developer, manufacturer and marketer of medical devices with approximately 29,000 employees and revenue of \$7.8 billion in 2006. For more than 25 years, Boston Scientific has advanced the practice of less-invasive medicine by providing a broad and deep portfolio of innovative products, technologies and services across a wide range of medical specialties. The Company's products help physicians and other medical professionals improve their patients' quality of life by providing alternatives to surgery.

Boston Scientific's mission is to improve the quality of patient care and the productivity of health care delivery through the development and advocacy of less-invasive medical devices and procedures.

DYN DIAGNOSTICS LTD.

P.O.Box 3063
Caesaria 38900
Tel: 057-6675352
Contact: Meirav Feingold
meirav@dyn.co.il

DYN Diagnostics Ltd. deals with marketing, sales, engineering and scientific support in the field of medical In Vitro Diagnostics (IVD) as well as Applied Science for life science research. DYN Diagnostics Ltd. is the sole representative in Israel of Roche Diagnostics GmbH, a world leading

company in the field of IVD. DYN Diagnostics also represents companies which complement Roche Diagnostics' product line in order to enable a proposal of a complete solution for the various diagnostic fields.

DYN Diagnostics, active in the Israeli market since 1990, has 17 years experience in implementing and assimilating diagnostic systems for various extents such as: hospital labs working 24 hours a day, regional labs and private laboratories as well as Near Patient Test devices.

DYN is experienced in various disciplines such as Biochemistry, Immunology, Hematology, Molecular Biology, Coagulation, Urinalysis, Blood Gas and Lab Organization.

ELDAN ELECTRONIC INSTRUMENTS CO. LTD.

P.O.Box 7641
Petach Tikva, 49170
Tel: 03-9264829
nir@eldan.biz

Eldan Electronic Instruments Co. Ltd. is a privately owned company established in 1960 and is a part of the Neopharm Group, the second largest supplier in the Israeli healthcare & scientific market. Eldan is one of the leading companies in providing sophisticated equipment, instrumentation and services to the scientific research and medical fields. Eldan provides top quality equipment according to its customers needs and represents leading international manufacturers and producers in the following areas: ultrasound systems, patient monitoring systems, home care products, resuscitation devices, ergometric systems, ECG systems, EP, respiratory care, and hospital supplies. In addition, Eldan provides high-quality services and has experience in conducting, training, managing and supervising clinical trials in Israel, on behalf of international companies as well as local ones. Our service-oriented approach to trials helps

meet client needs and results in a high level of customer satisfaction.

GEFFEN MEDICAL – BIOSITE

Contact: Lital Levi – Product Manager
Tel: 03-6900300, 052-5395656
lital.l@geffenmedical.com

Geffen Medical Ltd. is a privately held company, established in 1995. Geffen Medical's main line of business, as representatives of foreign companies, is the importing and marketing of cutting edge medical equipment and disposables in the Israeli health care market. Geffen Medical's main focus is in the field of medical aids and equipment for the treatment of diabetes.

Geffen Medical is proud to be the Israeli distributor of Biosite Incorporated, a leading bio-medical company commercializing proteomics discoveries for the advancement of medical diagnosis. Biosite has adopted a strategy that encompasses the diagnostic continuum from protein validation to patient care. Biosite is focused on developing novel diagnostics tests that are capable of immediately and accurately diagnosing and assessing critical conditions, which can take several hours using conventional testing methods. Today, Biosite technology is used in physician's office laboratories, more than 50% of all U.S. hospitals and in 40 other countries by clinicians who share our belief that a better, more rapid diagnosis can lead to better outcomes.

Biosite products in the cardiology field include rapid tests panels:

- Triage Cardiac Panel - CK-MB, myoglobin, and troponin I
- Triage Cardio ProfILER - CK-MB, myoglobin, troponin I and BNP
- Triage Profiler Shortness of Breath Panel - CK-MB, myoglobin, troponin I, BNP and D-dimer
- The Triage BNP Test

GSK GlaxoSmithKline Israel

25 Basel St. P.O.Box 10283
Petach Tikva 49002
Tel: 03-9297100
Contact: Einat Zour
einat.zour@gsk.com

GSK has a challenging and inspiring mission: to improve the quality of human life by enabling people to do more, feel better and live longer. This mission gives us the purpose to develop innovative medicines and products that help millions of people around the world. In fact, we believe we are the only pharmaceutical company researching both medicines and vaccines for the World Health Organization's three priority diseases – HIV/AIDS, tuberculosis and malaria, and are very proud to have developed some of the leading global medicines in these fields.

Headquartered in the UK and with operations based in the US, we are one of the industry leaders, with an estimated seven per cent of the world's pharmaceutical market. As a company with a firm foundation in science we spend more than £300,000 (US\$562,000) every hour to find new medicines.

MEDISON PHARMA LTD.

10 Hashiloach St., P.O.Box 7090
Petach-Tikva 49170, Israel
Tel: 03-9250250
Fax: 03-9225740
Medison@medison.co.il

Medison is a leading Israeli marketing group focused in the fields of high quality pharmaceutical products and diagnostics products. With over a decade of experience, we are uniquely placed to provide a complete A to Z spectrum of integrated services for international companies looking to enter or expand their presence in the Israeli healthcare market, Romania & Slovakia.

In the decade since our company was founded in 1996, we have built a unique set of skills for mid-sized pharmaceutical companies targeting Israel. This degree of A to Z spectrum of services has attracted biotechnology companies such as Biogen-Idec, Cephalon, Shire and Ipsen who find in Medison a specialist company that matches their own niche marketing needs.

Medison markets various products in the fields of cardiology, neurology, oncology, hematology, endocrinology, nephrology, dermatology, genetic disease, infections, gynecology, surgery & aesthetics.

MEDTRONIC PHYSIO CONTROL

41 Hameyasdim St.

P.O.Box 908

Even Yehuda 40500 Israel

Contact: Kevin Lev, Sales Manager

Tel: 09-891-2223, 054-6962818

Website: www.physiocontrol.com

kevin.lev@medtronic.com

For more than 50 years, Physio-Control, Inc., maker of renowned LIFEPAK defibrillators, has been developing technologies and designing devices that are legendary among first response professionals, clinical care providers and citizens everywhere. With over 650,000 LIFEPAK defibrillators in use, Physio-Control LIFEPAK is the global leader in external defibrillation and is the standard product in all Magen David Adom ambulances. Our offering includes a full range of services and complementary products that form an emergency response system. Data management software, round-the-clock technical service, training, medical assistance, and liability protection all work in partnership to help you perform the most critical task - saving a life. Paramedics, EMTs and firefighters trust our rugged and ultra-portable professional-grade tools. Clinical care providers choose our products to help them optimize patient care and improve operational effectiveness. Governments and employers partner with us to enhance public health and safety

through intuitive, accessible, and easy-to-use lifesaving products.

Physio-Control manufactures products for all tiers of a multi-level emergency response system, from trained lay responders (LIFEPAK CR+) to emergency medical technicians and paramedics (LIFEPAK 12, the most advanced multi-paramatered intensive care tool available on the market today which can be found in all of Magen David Adom's ALS vehicles), to hospital-based caregivers (LIFEPAK 20). These products are designed to adapt to the medical knowledge and training of the responder as well as the physical needs of the patient and the surrounding emergency conditions, enabling fast, smooth transitions from the scene through EMS to treatment at the hospital.

PFIZER – The World's Largest Drug Manufacturer

Pfizer Pharmaceuticals Israel Ltd.

9 Shenkar St., P.O.Box 12133

Herzliya Pituach 46725

Tel: 09-9700500

Fax: 09-9700501

Driven by initiative, innovation and daring, cousins Charles Pfizer and Ernest Erhardt emigrated from Germany to New York in 1849 and established the Pfizer Company, which was destined to eventually become the world's largest drug manufacturer.

Today, 158 years later, Pfizer remains at the cutting edge of scientific progress by virtue of dedication to the same values that motivated its founders: uncompromising quality, constant innovation and renewal, leadership, reliability, the patient's well-being and commitment to the community.

These humanitarian and ethical principles have led the company to unprecedented scientific breakthroughs and a wide-ranging scope of activity: The company's employees today number over 100,000 in 106 countries, with over 12,000 medical

studies being conducted concurrently and a public of 38 million patients whose health and quality of life is enhanced or prolonged by the most advanced medical products in the world.

In light of such social commitment, the world's largest drug manufacturer not only pays attention to, understands and responds to the needs of that public, but also has a strong belief in supporting its obligations to patients through corporate responsibility. Pfizer's corporate social policy is based on principles such as the basic right to good health, with no differentiation of religion, race or sex; the patient's right to be aware of the rights and services available to him/her; and the improvement of quality of life through a healthy lifestyle. This commitment is implemented worldwide by means of hands-on social involvement based on individual and group empowerment.

SANOFI-AVENTIS

P.O.Box 8090

Netanya 42710

Clexane contact: Orly Hazan 0522-517695

Plavix contact: Maria Miller 0526-026446

orly.hazan@sanofi-aventis.com

Sanofi-Aventis is the third largest pharmaceutical company in the world, leading in the research and development of new therapies in the fields of Atherothrombosis, Coagulation, Internal Medicine and Oncology.

The 2 leading products in Israel are:

Plavix, the ADP receptor that provides advanced protection for all patients at risk of atherothrombosis, as compared to other standard therapies, thus preventing atherothrombotic events.

Clexane, the most widely studied and used Low-Molecular-Weight-Heparin in the world. Numerous clinical studies have shown that Clexane safely and effectively treats certain cardiac conditions such as unstable angina (UA) or Non-Q Wave myocardial infarction (NQMI).

SCHERING PLOUGH ISRAEL A.G.

49 Hasivim St.

Petach-Tikva 49517, Israel

Tel: 03-9209000

Schering-Plough is committed to earning the trust of doctors, patients and customers every day. To gain trust we focus each day on becoming a champion for our stakeholders. Schering-Plough is building long-term relationships with our stakeholders based on mutual confidence. We're determined to increase access to better health care for all people. We are focused on becoming the best through: people, products and processes. The test of being a true champion is to never give up and to passionately strive for even better outcomes. As a health-care company, our aim is helping people worldwide live better and longer.

SHL TeleMedicine LTD.

90 Yigal Alon St.

Tel Aviv 67891

Contact: Shirley Katz

Tel: 054-6622216, 03-5633884

shirleyk@shahal.co.il

SHL TeleMedicine Ltd. specializes in developing and marketing advanced personal telemedicine systems as well as providing medical call center services to subscribers. Personal telemedicine is the transmission of medical data by an individual, from a remote location to a medical call center via standard telephone networks. With the help of sophisticated computer systems, call center medical staff use this data to diagnose and monitor subscribers' health, following proprietary guidance protocols, and to respond fast and effectively to their needs.

SHL's personal telemedicine systems are designed to improve quality of care and lifestyle for people suffering from various health conditions ranging from the high-risk and chronically ill to ordinary users of healthcare products and services who wish to take a more active role in managing their own health. In particular, the

company's telemedicine systems can be used to reduce emergency care response time for sufferers of potentially fatal cardiac episodes.

The company maintains international business operations and provides services in the USA through its fully owned subsidiary, Raytel Medical Corporation, a cardiovascular healthcare services provider, in selected European markets mainly through PHTS, a fully owned subsidiary, and at home in Israel.

SHL TeleMedicine holds a leading market position due to the company's experience gathered in 17-year track record, and long-term client base consisting of more than 300,000 clients, providing a reliable recurring revenue stream.

TEVA ISRAEL

P.O.Box 8077, Sapir Industrial Zone
Netanya 42504

Contact: Michal Rozin, Products Manager
Tel: 09-8639753, 054-8884246

Teva Pharmaceutical Industries Ltd. is a global pharmaceutical company specializing in the development, production and marketing of generic and proprietary branded pharmaceuticals and active pharmaceutical ingredients. Teva is among the top 20 pharmaceutical companies and among the largest generic pharmaceutical companies in the world. In Israel Teva markets products of other global pharmaceutical companies amongst which are AstraZeneca with Crestor and Atacand.

Crestor (rosuvastatin)

- Crestor is the most effective statin in lowering LDL-C with a beneficial effect on HDL-C.
- 82% of diabetic patients reach LDL-C goal levels with Crestor 10mg
- Crestor safety profile is similar to that of other statins

Crestor is now treating 10 million patients worldwide.

Atacand (cadensartan cilexetil)
Atacand (cadensartan cilexetil) is an angiotensin receptor blocker (ARB), indicated for treatment of hypertension and chronic heart failure (CHF). Atacand is the only ARB indicated for the treatment of CHF in combination with ACEI.

TZAMAL-JAKOB SOHN LTD.

P.O.Box 7004

Petach Tikva, 49170

Contact: Anat Mor

anatm@tzamal-medical.co.il

Tel: 073-7151111

Fax: 03-9245329

With over 30 years of experience in the medical equipment field, Tzamal-Jakobsohn knows how to get to the heart of healthcare instrumentation needs. The company offers the latest, sophisticated equipment and technology necessary for all types of surgical procedures, including extensive fieldwork in surgery, orthopedics, and cardiology. In the Cardiology field, Tzamal-Jakobsohn represents B. Braun/Aesculap, Hexacath, Vascular Solutions and AngioScore.

Major Sponsors



Sponsors

